Physician profile
Michele Doreen Burget
NPI 1730224304
$132,982.75
in general payments reported to CMS, 2019-2025
14 companies · $91K in 2025
The $91K reported for 2025 was more than what 99% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $74.46 · 2021: $58.13 · 2022: $73.98 · 2023: $19K · 2024: $23K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $91K · Royalty Or License: $42K · Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $90,675.29 |
| Royalty Or License | $41,673.00 |
| Food and Beverage | $263.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pediatric Alliance LLC | $132,348.29 | 2023-2025 | |
| Greer Laboratories, INC. | $109.81 | 2025 | Oralair |
| Sobi, INC | $92.56 | 2019 | |
| Corium, LLC | $76.49 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $66.26 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi Pasteur INC. | $65.37 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.35 | 2020-2021 | |
| Cranial Technologies, INC | $45.08 | 2020-2022 | |
| Kaleo, INC. | $37.13 | 2019-2020 | |
| Seqirus USA INC | $36.45 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Shire North American Group INC | $25.73 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.54 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $14.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$181,737.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Burget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.